Canopy Growth (FRA:11L) FFO per Share

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:11L Canopy Growth Corp FRA:11L
61 GF Score
Price €0.80
GF Value €0.65
Valuation Modestly Overvalued
! 3 Warning Signs
View Full Analysis

What is Canopy Growth FFO per Share?

FFO per Share only applies to REITs.

FRA:11L
61GF Score
Canopy Growth Corp FRA:11L
FFO per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Canopy Growth (FRA:11L) Overvalued in 2026?

Based on GuruFocus' analysis, Canopy Growth stock appears to be overvalued. The current stock price of €0.80 is trading 22.3% above its estimated GF Value™ of €0.65. GuruFocus considers Canopy Growth to be Modestly Overvalued.

Key valuation signals for FRA:11L:

  • FFO per Share:
  • GF Value™: €0.65 vs. price of €0.80 (22.3% above fair value)
  • GF Score™: 61/100 with 3 warning signs

No single metric tells the full story. See the FRA:11L stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Canopy Growth Business Description

Address 1 Hershey Drive, Smiths Falls, ON, CAN, K7A 0A8
Canopy Growth Corp is a cannabis company that produces, distributes, and sells a diverse range of cannabis and cannabis-related products for adult-use and medical purposes under a portfolio of distinct brands in Canada. The Company supplies cannabis products in Canada, Europe, and Australia. It is focused on the medical and adult-use cannabis markets in Canada, offering a broad portfolio of brands and formats for medical cannabis patients and adult-use consumers. The Company operates through two reportable segments: Cannabis, which generates maximum revenue and includes the production, distribution, and sale of cannabis and cannabis-related products, and Storz & Bickel, which includes the production, distribution, and sale of vaporizers and accessories.
61GF Score

Get the complete analysis for FRA:11L

FFO per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.80
Price
€0.65
GF Value